BMP and activin membrane-bound inhibitor regulate connective tissue growth factor controlling mesothelioma cell proliferation
- PMID: 36109807
- PMCID: PMC9479400
- DOI: 10.1186/s12885-022-10080-x
BMP and activin membrane-bound inhibitor regulate connective tissue growth factor controlling mesothelioma cell proliferation
Abstract
Background: Malignant mesothelioma (MM) is an aggressive mesothelial cell cancer type linked mainly to asbestos inhalation. MM characterizes by rapid progression and resistance to standard therapeutic modalities such as surgery, chemotherapy, and radiotherapy. Our previous studies have suggested that tumor cell-derived connective tissue growth factor (CTGF) regulates the proliferation of MM cells as well as the tumor growth in mouse xenograft models.
Methods: In this study, we knock downed the bone morphogenetic protein and activin membrane-bound inhibitor (BAMBI) and CTGF in MM cells and investigated the relationship between both and their impact on the cell cycle and cell proliferation.
Results: The knockdown of CTGF or BAMBI reduced MM cell proliferation. In contrast to CTGF knockdown which decreased BAMBI, knockdown of BAMBI increased CTGF levels. Knockdown of either BAMBI or CTGF reduced expression of the cell cycle regulators; cyclin D3, cyclin-dependent kinase (CDK)2, and CDK4. Further, in silico analysis revealed that higher BAMBI expression was associated with shorter overall survival rates among MM patients.
Conclusions: Our findings suggest that BAMBI is regulated by CTGF promoting mesothelioma growth by driving cell cycle progression. Therefore, the crosstalk between BAMBI and CTGF may be an effective therapeutic target for MM treatment.
Keywords: BAMBI; CTGF; Malignant mesothelioma; Proliferation; Cell cycle.
© 2022. The Author(s).
Conflict of interest statement
The authors have no conflict of interest.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9479400/bin/12885_2022_10080_Fig1_HTML.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9479400/bin/12885_2022_10080_Fig2_HTML.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9479400/bin/12885_2022_10080_Fig3_HTML.gif)
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9479400/bin/12885_2022_10080_Fig4_HTML.gif)
Similar articles
-
Expression and Function of BMP and Activin Membrane-Bound Inhibitor (BAMBI) in Chronic Liver Diseases and Hepatocellular Carcinoma.Int J Mol Sci. 2023 Feb 9;24(4):3473. doi: 10.3390/ijms24043473. Int J Mol Sci. 2023. PMID: 36834884 Free PMC article. Review.
-
The pseudoreceptor BMP and activin membrane-bound inhibitor positively modulates Wnt/beta-catenin signaling.J Biol Chem. 2008 Nov 28;283(48):33053-8. doi: 10.1074/jbc.M804039200. Epub 2008 Oct 6. J Biol Chem. 2008. PMID: 18838381 Free PMC article.
-
BAMBI (bone morphogenetic protein and activin membrane-bound inhibitor) reveals the involvement of the transforming growth factor-beta family in pain modulation.J Neurosci. 2010 Jan 27;30(4):1502-11. doi: 10.1523/JNEUROSCI.2584-09.2010. J Neurosci. 2010. PMID: 20107078 Free PMC article.
-
Identification of BMP and activin membrane-bound inhibitor (BAMBI) as a potent negative regulator of adipogenesis and modulator of autocrine/paracrine adipogenic factors.Diabetes. 2012 Jan;61(1):124-36. doi: 10.2337/db11-0998. Diabetes. 2012. PMID: 22187378 Free PMC article.
-
BMP and activin receptor membrane bound inhibitor: BAMBI has multiple roles in gene expression and diseases (Review).Exp Ther Med. 2023 Nov 22;27(1):28. doi: 10.3892/etm.2023.12316. eCollection 2024 Jan. Exp Ther Med. 2023. PMID: 38125356 Free PMC article. Review.
References
-
- Cavone D, Caputi A, De Maria L, Cannone E, Mansi F, Birtolo F, et al. Epidemiology of Mesothelioma. Environments. 2019;6(7):1–18. doi: 10.3390/environments6070076. - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous